A controlled trial of amantadine in drug-induced extrapyramidal disorders.

No abstract is available for this paper.

• Publication year

  1976

• Venue

  Psychopharmacology bulletin

• Publication date

  1976-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1001/ARCHPSYC.1976.01770050055008PMID 18755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• THERAPEUTIC REVERSAL WITH BENZTROPINE IN SCHIZOPHRENICS: PRACTICAL AND THEORETICAL SIGNIFICANCE

  1975cited by this paper
• Effect of cholinergic and anticholinergic agents on tardive dyskinesia 1

  1974cited by this paper
• A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel).

  1973cited by this paper
• Effects of mode of management on plasma chlorpromazine in psychiatric patients

  1973cited by this paper
• AMANTADINE THERAPY IN PARKINSONISM

  1972cited by this paper
• Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism

  1972cited by this paper
• Chlorpromazine and growth.

  1971cited by this paper
• Uses and toxicity of belladonna alkaloids and synthetic anticholinergics.

  1971cited by this paper
• The antiparkinson properties of amantadine in drug-induced parkinsonism.

  1971cited by this paper
• Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.

  1971cited by this paper
• Amantadine for dyskinesia tarda.

  1971cited by this paper
• Amantadine hydrochloride treatment of tardive dyskinesia.

  1971cited by this paper
• Antiparkinson drug overuse.

  1970cited by this paper
• Antagonism by amantadine of prochlorpemazine‐induced catalepsy

  1970cited by this paper
• Controlled trial of amantadine hydrochloride in Parkinson's disease.

  1970cited by this paper
• AMANTADINE HYDROCHLORIDE IN THE TREATMENT OF PARKINSONISM A CONTROLLED TRIAL

  1970cited by this paper
• Amantadine in the treatment of Parkinson's disease.

  1969cited by this paper
• The toxicologic and pharmacologic properties of amantadine hydrochloride.

  1969cited by this paper
• Dyskinesia and neuroleptics.

  1968cited by this paper
• Drug-induced extrapyramidal symptoms and their relations to clinical efficacy.

  1967cited by this paper

• Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia

  2024cites this paper
• Evaluation and Management of Tremor.

  2024cites this paper
• Improved Treatment Outcome with Haloperidol Decanoate and Amantadine in an Adolescent with Schizoaffective Disorder

  2023cites this paper
• “Unvoluntary” Movement Disorders: Distinguishing between Tics, Akathisia, Restless Legs, and Stereotypies

  2023cites this paper
• Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic

  2022cites this paper
• Treatment of antipsychotic-induced parkinsonism in schizophrenic patients

  2021cites this paper
• First-Episode & Early Psychosis in Transition-Age Youth

  2021cites this paper
• Functional Improvement of Tacrolimus-Induced Parkinsonism With Amantadine After Liver Transplantation: A Case Report

  2021cites this paper
• Revisiting Amantadine as A Treatment for Drug-Induced Movement Disorders

  2020cites this paper
• Early amantadine treatment reduces the risk of death in patients with large hemisphere infarctions:a Chinese hospital-based study

  2020cites this paper
• The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder.

  2019cites this paper
• DIAGNOSTIC METHODS OF ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDE DISORDERS

  2019cites this paper
• Overcoming barriers to effective management of tardive dyskinesia

  2019cites this paper
• Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management

  2018cites this paper
• Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia.

  2018cites this paper
• Anticholinergic medication for antipsychotic-induced tardive dyskinesia.

  2018cites this paper
• The Assessment and Treatment of Antipsychotic-Induced Akathisia

  2018cites this paper
• Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.

  2018cites this paper
• Targeting the FKBP51/GR/Hsp90 Complex to Identify Functionally Relevant Treatments for Depression and PTSD.

  2018cites this paper
• Neurologic Complications of Commonly Used Drugs in the Hospital Setting

  2016cites this paper
• Association Between Serum Anticholinergic Activity and Psychiatric Symptoms of Chronic Schizophrenia

  2015cites this paper
• A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs by D. G. Cunningham Owens

  2014cites this paper
• Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.

  2014cites this paper
• A Bibliometric Analysis of Research in Psychopharmacology by Psychology Departments (1987–2007)

  2010cites this paper
• Textbook of Clinical Neuropsychiatry, Second Edition

  2008cites this paper
• Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia.

  2006cites this paper
• CHAPTER M1 – Drug-Induced Movement Disorders

  2005cites this paper
• Brain electrical activity changes in treatment refractory schizophrenics after olanzapine treatment.

  2005cites this paper
• Amantadine and the glutamate hypothesis of schizophrenia Experiences in the treatment of neuroleptic malignant syndrome

  2005cites this paper
• New Approaches To The Treatment Of Dopamine Blocking Agent- Induced Movement Disorders

  2004cites this paper
• Acute And Tardive Drug-induced Akathisia

  2004cites this paper
• Neuroleptic-induced akathisia: a review

  2004cites this paper
• Estudio comparativo respecto a consideraciones clínicas y psicoterapéuticas en el tratamiento biopsicosocial de la esquizofrenia. Parte II

  2004cites this paper
• Acute extrapyramidal side effects: Serum levels of neuroleptics and anticholinergics

  2004cites this paper
• Diurnal variations of extrapyramidal symptoms induced by haloperidol in schizophrenic subjects.

  2003cites this paper
• Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.

  2003cites this paper
• Predictor index of mortality in dementia patients upon entry into long-term care.

  2001cites this paper
• Characteristics and outcomes of dementia residents in an assisted living facility

  2000cites this paper
• What can we do about acute extrapyramidal symptoms?

  2000cites this paper
• Managing Antipsychotic-Induced Acute and Chronic Akathisia

  2000cites this paper
• Predictors of mortality in dementia patients upon entry into long-term care

  2000cites this paper
• Schizophrenic patients show facial reactions to emotional facial expressions.

  1999cites this paper
• Managing Antipsychotic-Induced Parkinsonism

  1999cites this paper
• Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists

  1999cites this paper
• NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.

  1999cites this paper
• Treatment of tardive akathisia with clonidine: a case report.

  1999cites this paper
• Stability of emotional responding in schizophrenia

  1999cites this paper
• Emotional responding in deficit and non-deficit schizophrenia.

  1999cites this paper
• Adjustment to residential placement in Alzheimer disease patients: does premorbid personality matter?

  1998influential citation
• Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol.

  1998cites this paper
• Psychiatry in the geriatric neurology practice.

  1998cites this paper
• BRIEF REPORTS Changes in Symptoms Acid with Amantadine Chronic Schizophrenia and Plasma Homovanillic Hydrochloride in

  1997cites this paper
• Cholinergic medication for neuroleptic-induced tardive dyskinesia.

  1997cites this paper
• Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.

  1997cites this paper
• CT measurement of suprasellar cistern predicts rate of cognitive decline in Alzheimer's disease

  1996cites this paper
• DRUG‐INDUCED AKATHISIA REVISITED

  1996cites this paper
• Management of Acute Antipsychotic-Induced Extrapyramidal Syndromes

  1996cites this paper
• Clinically Significant Interactions of Psychotropic Agents with Antipsychotic Drugs

  1996cites this paper
• Predicting rate of cognitive decline in probable Alzheimer's disease.

  1996cites this paper
• Akathisia and Restless Legs: Conclusions

  1995cites this paper
• The Identification and Management of Drug-Induced Akathisia

  1995cites this paper
• Nonsteroidal anti-inflammatory drugs in Alzheimer's disease

  1995cites this paper
• Effects of electroconvulsive treatment on somatostattn, neuropeptide Y, endothelin, and neurokinin a concentrations in cerebrospinal fluid of depressed patients: A pilot study

  1995cites this paper
• Therapeutic brain concentration of the NMDA receptor antagonist amantadine.

  1995cites this paper
• Treatment of Acute Neuroleptic‐Induced Movement Disorders

  1994cites this paper
• Antiparkinsonian Drugs in the Treatment of Neuroleptic-Induced Extrapyramidal Symptoms

  1994cites this paper
• Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.

  1994cites this paper
• The role of excitatory amino acids in experimental models of Parkinson's disease

  1994cites this paper
• Die medikamenteninduzierte Akathisie

  1993cites this paper
• Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone.

  1993cites this paper
• The effects of neuroleptics on facial action in schizophrenic patients.

  1992cites this paper
• Neuroleptic-induced Movement Disorders

  1992cites this paper
• Spasmodic Torticollis — Review of 220 Patients

  1991cites this paper
• Acute psychosis after amantadine overdose.

  1990cites this paper
• Treatment of tardive akathisia with clonidine.

  1990cites this paper
• Confusion.

  1990cites this paper
• Phänomenologie und Therapie der Neuroleptika-induzierten Akathisie - eine Literaturübersicht

  1989cites this paper
• Effect of amantadine on motility of reserpinized mice as a function of brain biogenic amines and mouse strains.

  1989cites this paper
• Amitriptyline in the treatment of neuroleptic-induced akathisia.

  1988cites this paper
• Failure of amantadine hydrochloride to alter immune responses in the experimental allergic encephalomyelitis model of neuroautoimmune disease.

  1988cites this paper
• Der Beitrag des analytischen Biochemikers zur Therapieresistenz der Schizophrenie

  1988cites this paper
• Bupropion and thiothixene versus placebo and thiothixene in the treatment of depression in schizophrenia

  1988cites this paper
• Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms.

  1988cites this paper
• Clinical Pharmacokinetics of Amantadine Hydrochloride

  1988cites this paper
• Amantadine for levodopa resistant parkinsonism.

  1987cites this paper
• Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys

  1987cites this paper
• Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia.

  1987cites this paper
• Movement Disorders and Neuroleptic Medication

  1986cites this paper
• A Controlled Assessment of Propranolol in the Treatment of Neuroleptic-Induced Akathisia

  1986cites this paper
• PET studies of cerebral glucose metabolism in idiopathic torticollis

  1986cites this paper
• Opioid responsiveness in patients with neuroleptic‐induced akathisia

  1986cites this paper
• Exacerbation of schizophrenia associated with amantadine.

  1986cites this paper
• Antipsychotic agents: a clinical update.

  1985cites this paper
• Treatment of Parkinson’s disease with agents other than Levodopa and Dopamine Agonists: controversies and new approaches

  1984cites this paper
• Recognizing and managing akathisia.

  1984cites this paper
• Use of clonidine in treating neuroleptic-induced akathisia.

  1984cites this paper
• Diazepam in Tardive Dyskinesia

  1983cites this paper
• Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys

  1983cites this paper
• Management of akathisia in a severely retarded adolescent male with help of an anticholinergic drug assay.

  1981cites this paper
• 1 Aminoadamantane Derivatives

  1981cites this paper